Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.

Aditya John Binu; Nitin Kapoor
Abstract
Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.
Journal HEART INTERNATIONAL
ISSN 2036-2579
Published 01 Jan 2024
Volume 18
Issue 1
Pages 3-4
DOI 10.17925/HI.2024.18.1.1
Type Editorial
Sponsorship